Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Multiple myeloma (MM) is a fatal hematological cancer requiring novel therapeutic strategies.
• Current treatments for MM have limitations, necessitating the development of innovative approaches.

Purpose of the Study:

• To develop and evaluate novel chimeric antigen receptor T-cell (CAR-T) therapies targeting CS1 and bispecific CS1-BCMA antigens for multiple myeloma.
• To assess the efficacy of CS1-CAR-T cells and bispecific CS1-BCMA-CAR-T cells in targeting and eliminating multiple myeloma cells.

Main Methods:

• Generation of a novel CS1-specific antibody (clone 7A8D5) for CS1-CAR-T cell development.
• Construction and testing of CS1-CAR-T cells and bispecific CS1-BCMA-41BB-CD3 CAR-T cells.
• In vitro assays to assess target cell killing and cytokine secretion (IFN-gamma).
• In vivo studies using MM1S multiple myeloma tumor models to evaluate tumor growth inhibition.

Main Results:

• CS1-CAR-T cells demonstrated specific killing of CS1-expressing target cells and multiple myeloma cells, with IFN-gamma secretion.
• Bispecific CS1-BCMA-CAR-T cells effectively killed both CS1 and BCMA expressing target cells, including CS1/BCMA-positive multiple myeloma cells, and secreted IFN-gamma.
• Both CS1-CAR-T cells and bispecific CS1-BCMA-CAR-T cells significantly inhibited MM1S multiple myeloma tumor growth in vivo.

Conclusions:

• Novel CS1-CAR-T cells and bispecific CS1-BCMA-CAR-T cells are effective in targeting and eliminating multiple myeloma cells.
• These CAR-T cell therapies demonstrate significant anti-tumor activity in preclinical models.
• The findings provide a strong foundation for future clinical trials of these novel immunotherapies for multiple myeloma.